TLSIW
TriSalus Life Sciences Inc.NASDAQ
Key Statistics
Market Cap
—
P/E Ratio
—
EPS
—
Beta
0.56
52W High
$2.94
52W Low
$0.44
50-Day MA
$0.99
200-Day MA
$1.33
Dividend Yield
—
Profit Margin
-60.90%
Forward P/E
—
PEG Ratio
—
About TriSalus Life Sciences Inc.
TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company is headquartered in Westminster, Colorado.
Fundamentals
| Revenue (TTM) | $44.88M |
| Gross Profit (TTM) | $38.18M |
| EBITDA | $-27.44M |
| Operating Margin | -94.50% |
| Return on Equity | 0.00% |
| Return on Assets | -35.20% |
| Revenue/Share (TTM) | $1.02 |
| Book Value | $-0.68 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -2.90% |
| Shares Outstanding | 0 |
| Float | $49.45M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Historical Volatility
HV 10-Day
246.94%
HV 20-Day
183.42%
HV 30-Day
157.90%
HV 60-Day
162.96%
HV Rank
—
Volatility is currently expanding
Data last updated: 5/25/2026